ESLA Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 mai 2024 @ 22:00):

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States...

Stats
Dagens volum	7 720.00
Gjennomsnittsvolum	27 900.00
Markedsverdi	34.44M
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.51
ATR14	$0.00700 (0.74%)

Insider Trading

Date	Person	Action	type
2023-09-29	Xu Jiandong	Sell	Common Stock
2023-09-29	Roberts Marsha	Buy
2023-09-29	Xu Pei	Buy
2023-09-29	Liu Cheng	Sell	Common Stock
2023-09-29	Wu Xuejun Janelle	Buy

INSIDER POWER
-100.00
Last 9 transactions
Buy: 141 970 \| Sell: 255 000

Estrella Immunopharma, Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Estrella Immunopharma, Økonomi

Annual	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-0.170

FY	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-0.170

Financial Reports:

No articles found.

Estrella Immunopharma, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Estrella Immunopharma,

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company\'s lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene\'s product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.